{"filing":{"accession_number":"0001213900-26-099451","cik":"0001985062","ticker":"PBMWW","company_name":"PSYENCE BIOMEDICAL LTD.","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ea0305327-6k_psyence.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390026099451/ea0305327-6k_psyence.htm"},"events":[{"id":33116,"run_id":30442,"accession_number":"0001213900-26-099451","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Psyence BioMed announced the formation of Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary designed to coordinate ibogaine development, manufacturing, regulatory engagement, and potential clinical activities. This is a material operational and strategic restructuring—establishing a dedicated U.S. vehicle to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs (subject to definitive licensing), coordinate supply and manufacturing, and serve as the counterparty for federal agencies and clinical partners. While not a discrete M\u0026A transaction, the creation of this subsidiary and the intended licensing arrangement represent a significant strategic repositioning to advance the company's U.S. ibogaine program in response to recent federal policy developments (Executive Order of April 18, 2026, and coordinated federal implementation in July 2026).","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36470,"accession_number":"0001213900-26-099451","item_number":"EX-99.1","item_title":"ea030532701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Psyence BioMed announced the formation of Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary designed to coordinate ibogaine development, manufacturing, regulatory engagement, and potential clinical activities. This is a material operational and strategic restructuring—establishing a dedicated U.S. vehicle to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs (subject to definitive licensing), coordinate supply and manufacturing, and serve as the counterparty for federal agencies and clinical partners. While not a discrete M\u0026A transaction, the creation of this subsidiary and the intended licensing arrangement represent a significant strategic repositioning to advance the company's U.S. ibogaine program in response to recent federal policy developments (Executive Order of April 18, 2026, and coordinated federal implementation in July 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:34:41.568882+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36470,"accession_number":"0001213900-26-099451","item_number":"EX-99.1","item_title":"ea030532701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Psyence BioMed announced the formation of Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary designed to coordinate ibogaine development, manufacturing, regulatory engagement, and potential clinical activities. This is a material operational and strategic restructuring—establishing a dedicated U.S. vehicle to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs (subject to definitive licensing), coordinate supply and manufacturing, and serve as the counterparty for federal agencies and clinical partners. While not a discrete M\u0026A transaction, the creation of this subsidiary and the intended licensing arrangement represent a significant strategic repositioning to advance the company's U.S. ibogaine program in response to recent federal policy developments (Executive Order of April 18, 2026, and coordinated federal implementation in July 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:34:41.568882+00:00","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-14"}]}